Cite
HARVARD Citation
Rojas, J. et al. (2021). Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial. Lancet. 8 (8), pp. e463-e473. [Online].